It is widely accepted that the earlier you treat neovascular age-related macular degeneration, the better the patient’s final visual outcome will likely be. Early treatment requires early detection. True early detection, before a patient experiences visual symptoms, requires more than just an Amsler grid.
Introducing a major technological advancement for the daily monitoring of age-related macular degeneration: The ForeseeHome AMD Monitoring Program.
ForeseeHome is the first FDA cleared system for home-based monitoring of patients at risk of vision loss from wet age-related macular degeneration and the first biotelemetry device in ophthalmology.
In a large clinical study of 1,520 patients, results showed that the majority of patients who used ForeseeHome regularly were able to keep good, functional vision (20/40 or better) when wet AMD was detected compared to those patients in the study who only used other detection methods, such as the Amsler grid.
94% of ForeseHome patients that used the device as directed and converted to wet AMD kept their functional vision vs only 62% of patients using other detection methods.
The ForeseeHome AMD Monitoring Program links patients and doctors between regular eye exams, providing the advanced frequent monitoring solution needed for true early detection.
The ForeseeHome can detect changes in metamorphopsia, often before the patient notices any visual symptoms, providing important early indications of the possible development of wet AMD. Detection of wet AMD when the patient is asymptomatic, with excellent visual acuity and small lesion size, provides the opportunity for the most effective treatment.
The ForeseeHome AMD Monitoring Program can help you preserve your patients’ vision.
The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation. The ForeseeHome is not intended to diagnose; diagnosis is the responsibility of the prescribing eye-care professional.